Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 2
2020 7
2021 5
2022 1
2023 2
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.
Seidu S, Alabraba V, Davies S, Newland-Jones P, Fernando K, Bain SC, Diggle J, Evans M, James J, Kanumilli N, Milne N, Viljoen A, Wheeler DC, Wilding JPH. Seidu S, et al. Among authors: newland jones p. Diabetes Ther. 2024 May;15(5):1099-1124. doi: 10.1007/s13300-024-01550-5. Epub 2024 Apr 5. Diabetes Ther. 2024. PMID: 38578397 Free PMC article. Review.
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice.
Ali A, Bain S, Hicks D, Newland Jones P, Patel DC, Evans M, Fernando K, James J, Milne N, Viljoen A, Wilding J; As part of The Improving Diabetes Steering Committee. Ali A, et al. Among authors: newland jones p. Diabetes Ther. 2019 Oct;10(5):1595-1622. doi: 10.1007/s13300-019-0657-8. Epub 2019 Jul 9. Diabetes Ther. 2019. PMID: 31290126 Free PMC article. Review.
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
Wheeler DC, James J, Patel D, Viljoen A, Ali A, Evans M, Fernando K, Hicks D, Milne N, Newland-Jones P, Wilding J; as part of the Improving Diabetes Steering Committee. Wheeler DC, et al. Among authors: newland jones p. Diabetes Ther. 2020 Dec;11(12):2757-2774. doi: 10.1007/s13300-020-00930-x. Epub 2020 Sep 29. Diabetes Ther. 2020. PMID: 32996085 Free PMC article. Review.
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review.
Wilding JPH, Evans M, Fernando K, Gorriz JL, Cebrian A, Diggle J, Hicks D, James J, Newland-Jones P, Ali A, Bain S, Da Porto A, Patel D, Viljoen A, Wheeler DC, Del Prato S. Wilding JPH, et al. Among authors: newland jones p. Diabetes Ther. 2022 May;13(5):847-872. doi: 10.1007/s13300-022-01228-w. Epub 2022 Mar 20. Diabetes Ther. 2022. PMID: 35307801 Free PMC article. Review.
New Guidance on Managing Inpatient Hyperglycaemia during the COVID-19 Pandemic.
Rayman G, Lumb A, Kennon B, Cottrell C, Nagi D, Page E, Voigt D, Courtney H, Atkins H, Platts J, Higgins K, Dhatariya K, Patel M, Narendran P, Kar P, Newland-Jones P, Stewart R, Burr O, Thomas S. Rayman G, et al. Among authors: newland jones p. Diabet Med. 2020 Jul;37(7):1210-1213. doi: 10.1111/dme.14327. Epub 2020 Jun 8. Diabet Med. 2020. PMID: 32418245 No abstract available.
Guidelines for the management of diabetes services and patients during the COVID-19 pandemic.
Rayman G, Lumb A, Kennon B, Cottrell C, Nagi D, Page E, Voigt D, Courtney H, Atkins H, Platts J, Higgins K, Dhatariya K, Patel M, Narendran P, Kar P, Newland-Jones P, Stewart R, Burr O, Thomas S; London Inpatient Diabetes Network-COVID-19. Rayman G, et al. Among authors: newland jones p. Diabet Med. 2020 Jul;37(7):1087-1089. doi: 10.1111/dme.14316. Epub 2020 May 17. Diabet Med. 2020. PMID: 32365233
20 results